Your SlideShare is downloading. ×
  • Like
Otb amh isge2010-1
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply
Published

 

Published in Health & Medicine
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
85
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
5
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. AMH - an eligible marker of ovarianfunction for oncological patientsundergoing ovarian tissue bankingMarkus Lipovac, MD*, Gregor Rudelstorfer**, MD,Martin Imhof, MD**General Hospital KorneuburgDepartment for Obstetrics and Gynaecology**Medical University of ViennaDepartment for Gynaecological Endocrinologyand Reproductive Medicine
  • 2. • Chemotherapy with alkylating agents– e.g. Cyclophosphamide• Radiation (LD 50 of the ovary 4 Gy)– bone marrow TX - radiation > 20 GyReduction of Primordial Follicle ReserveMeirow D.; NugentD.: The effects of radiotherapy and chemotherapy on femalereproduction. Hum.Reprod. Update 2001; 7: 535-43
  • 3. Risk estimation of ovarian toxicity of differentchemotherapeutic agentsCyclophosphamidChlorambucilMelphalanBusulfanProcarbazineNitroureaMustinCytosinarabinosidIfosophamidCisplatinAdriamycinEpirubicinMethotrexat5-FluoruracilVincristinBleomycinVinblastinActinomycinOxaliplatinTaxansIrinotecanMonoclonal ABThyrosinkinase-Inhibitorshigh riskunknown riskintermediate risklow riskSonmezer M, Oktay K. Fertility preservation in female patients.Hum Reprod Update 2004; 10: 251–66
  • 4. Damage of Ovarian Structure- impairment of fertility- premature menopauseDue to ovarian damage increasing riskof POF resulting in
  • 5. Ovarian Tissue BankingRestoration of fertility and hormone -production after retransplantation of ovarian tissueCryopreservation of the ovarian tissue (primordialfollicle reserve)Therapy of malignancies e.g.: Leukaemia
  • 6. How to assess the patients ovarian reserveafter completion of the anti-cancer therapy?Ovarian Tissue Banking
  • 7. - Clinical parameters: menospausal symptoms like hotflushes, absence of menstrual bleeding, etc.- Analysis of common ovarian reserve markers like FSH,Inhibin B, EFORTOvarian Tissue BankingAssessment of ovarian reserve
  • 8. AMH – a sensitive marker for ovarian aging- A member of the transforming growth factor-βsuperfamily.- Is produced in the ovary by granulosa cells ofgrowing preantral and small antral follicles.- AMH concentrations correlate well with antral folliclecount and age, and less strongly with inhibin B andFSH levelsDe Vet A, Laven JS, de Jong FH, Themmen AP, Fauser BC. Anti-mullerian hormone serum hormone levels: aputative marker for ovarian aging. Fertil Steril 2002;77:357-362Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-mullerian hormone is morestrongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod2003;18: 323-327
  • 9. Question:Is AMH also an eligible marker of ovarianfunction for praemenopausal oncologicalpatients with ovarian cryopreservation?
  • 10. - AMH before and after oncological treatment (patients in remission)out of fresh frozen plasma were measured- Assessment of ovarian function through clinical symptoms ofmenopause- Evaluation of used oncological treatments- Statistical interrelations of AMH before and after oncologicaltreatmentMeasures
  • 11. Results
  • 12. A significant decrease of the AMH-levels of all patients afteroncological therapy could be observedResultsAMH before therapyAMH after therapyvalueinpM
  • 13. - 18 patients out of 74 were analysed- a significant decrease of AMH in all patients wasobserved (p=0,002)- 66% of the patients suffered from POF (p=0,01)- mean AMH before therapy was 15,35 pM(0,01-55,07 pM) and after 1,04 pM (0,01-5,43 pM).Results
  • 14. - Patients who received one cycle ofchemotherapy before OTB showed significantlower AMH-levels (p=0,045)- lower AMH-levels were observed in patientswithout menstruation (p=0,015)- lower AMH-levels were observed in patientsshowing menopausal symptoms (p=0,032) aftertheir oncological treatment.Results
  • 15. - These preliminary data suggets AMH as a proper markerof ovarian function of OTB-patients undergoingoncological therapy- The grade of ovarian damage correlates with the AMH-level- The level of AMH before therapy gives no evidence ofthe individual ovarian outcome of an oncological therapy- More data is necessary to confirm these findings.Conclusion
  • 16. Grazie per la vostra attenzione !!!AMH - an eligible marker of ovarian function foroncological patients undergoing ovarian tissue bankingMarkus Lipovac, MD*, Gregor Rudelstorfer**, MD, Martin Imhof, MD*
  • 17. Low RisikWilms TumorNon-Hodgkin LymphomaHodgkin LymphomaNongenital RhabomyosarkomaOsteosarkomaEpithelialCA of CervixEwing SarkomaKolorectal CAIntermediate RiskBreast CA Stadium I -IIHigh RisikLeukaemiaNeuroblastomaAdenoCA of CervixGenitalRhabdomyosarkomaBreastCA Stadium III-IVAfter: Oktay KH, Yih M: Preliminary experience withorthotopic and heterotopic transplantation ofovarian cortical strips Semin Reprod Med2002,20(1):63-74Frequency of ovarian metastasisOvarian Tissue Banking
  • 18. Ovarian reserve markers in use– Endocrine markers: early FSH, Inhibin B, AMH,different stimulation tests (e.g. clomiphene citrat test,EFORT- exogenous FSH ovarian reserve test )– Ultrasoundmarkers: antral follicle count, ovarianvolume and ovarian perfussion (US)
  • 19. Ovarian Tissue BankingInclusion criteria of the ongoing OTB-Study- Limited patient age: < 37 a- FSH – level < 10- Operation must be possible- No radiation until ovarian tissue withdrawal- Early stage of chemotherapy- Informed consent